[go: up one dir, main page]

NO20003107L - FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR - Google Patents

FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR

Info

Publication number
NO20003107L
NO20003107L NO20003107A NO20003107A NO20003107L NO 20003107 L NO20003107 L NO 20003107L NO 20003107 A NO20003107 A NO 20003107A NO 20003107 A NO20003107 A NO 20003107A NO 20003107 L NO20003107 L NO 20003107L
Authority
NO
Norway
Prior art keywords
quantification
reagents
solid phase
phase reactions
fluorine nmr
Prior art date
Application number
NO20003107A
Other languages
English (en)
Other versions
NO20003107D0 (no
Inventor
Vasant K Nagulapalli
Edward Orton
John E Airey
Paul H Krolikowski
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1997/023920 external-priority patent/WO1998029376A1/en
Priority claimed from PCT/US1998/026512 external-priority patent/WO1999031491A1/en
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of NO20003107D0 publication Critical patent/NO20003107D0/no
Publication of NO20003107L publication Critical patent/NO20003107L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20003107A 1997-10-17 2000-06-16 FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR NO20003107L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6231897P 1997-10-17 1997-10-17
US6590297P 1997-11-17 1997-11-17
PCT/US1997/023920 WO1998029376A1 (en) 1996-12-19 1997-12-17 Process for the solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid compounds
PCT/US1998/026512 WO1999031491A1 (en) 1997-12-17 1998-12-14 Method and reagents for the quantification of solid-phase reactions using fluorine nmr

Publications (2)

Publication Number Publication Date
NO20003107D0 NO20003107D0 (no) 2000-06-16
NO20003107L true NO20003107L (no) 2000-07-26

Family

ID=26742119

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20001962A NO20001962L (no) 1997-10-17 2000-04-14 Terapeutisk anvendelse av kinolinderivater
NO20003107A NO20003107L (no) 1997-10-17 2000-06-16 FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20001962A NO20001962L (no) 1997-10-17 2000-04-14 Terapeutisk anvendelse av kinolinderivater

Country Status (17)

Country Link
US (1) US6376512B1 (no)
EP (1) EP1030665A4 (no)
JP (1) JP2001520193A (no)
KR (1) KR20010024533A (no)
CN (1) CN1302206A (no)
AP (1) AP2000001786A0 (no)
AU (1) AU9696198A (no)
BG (1) BG104432A (no)
BR (1) BR9814087A (no)
CA (1) CA2306825A1 (no)
EA (1) EA200000427A1 (no)
HU (1) HUP0101022A1 (no)
IL (1) IL135673A0 (no)
NO (2) NO20001962L (no)
OA (1) OA11371A (no)
PL (1) PL344977A1 (no)
WO (1) WO1999020275A1 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200100558A (et) 1999-04-28 2002-12-16 Aventis Pharma Deutschland Gmbh Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
CN101070316A (zh) 1999-04-28 2007-11-14 萨诺费－阿文蒂斯德国有限公司 作为ppar受体配体的二芳基酸衍生物
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
TW200514783A (en) 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP2001261654A (ja) * 2000-03-21 2001-09-26 Mitsui Chemicals Inc キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DE60139025D1 (de) 2000-12-28 2009-07-30 Takeda Pharmaceutical Alkansäurederivate, verfahren zu deren herstellung und deren verwendung
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
BRPI0206641B8 (pt) 2001-01-26 2021-05-25 Merck Sharp & Dohme uso de um inibidor da absorção de esteróis
SK288217B6 (sk) 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
IL159320A0 (en) * 2001-06-12 2004-06-01 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
DE60216300T2 (de) 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
TWI282784B (en) 2002-06-20 2007-06-21 Astrazeneca Ab Therapeutic agents
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
AU2003291719A1 (en) 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CA2517573C (en) 2003-03-07 2011-12-06 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN100482649C (zh) 2003-09-17 2009-04-29 诺瓦提斯公司 有机化合物
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
CA2613365C (en) 2005-06-30 2013-08-13 Novo-Nordisk A/S Phenoxy acetic acids as ppar delta activators
RU2008108221A (ru) * 2005-09-07 2009-10-20 Плекссикон, Инк. (Us) Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом)
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
AU2007292883B2 (en) 2006-09-08 2013-09-05 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
NZ588374A (en) * 2008-04-30 2012-11-30 Wellstat Therapeutics Corp Tetrazole compounds for reducing uric acid
BRPI1011319A2 (pt) 2009-06-09 2016-06-21 California Capital Equity Llc derivados de triazina benzil-substituídos e suas aplicações terapêuticas
AU2010258853B2 (en) 2009-06-09 2014-07-31 Nantbio, Inc. Triazine derivatives and their therapeutical applications
EP2440048B8 (en) 2009-06-09 2015-12-16 NantBioScience, Inc. Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
WO2012007877A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
ES2526981T3 (es) 2010-07-12 2015-01-19 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2015157187A1 (en) * 2014-04-06 2015-10-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
CA3187998A1 (en) * 2020-08-04 2022-02-10 Angela ZAMPELLA Quinoline compounds as selective and/or dual modulators of bile acid receptors and leukotriene cysteinyl receptors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920130A (en) * 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
ATE177083T1 (de) * 1993-11-29 1999-03-15 Merrell Pharma Inc Benzolsulfonyliminderivate als inhibitoren der il-1 wirkung
DE69512495T2 (de) * 1994-10-27 2000-02-03 Asahi Glass Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von Chinolin-2-yl-benzoesäure
AU1529897A (en) * 1996-01-02 1997-07-28 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds

Also Published As

Publication number Publication date
IL135673A0 (en) 2001-05-20
US6376512B1 (en) 2002-04-23
WO1999020275A1 (en) 1999-04-29
AP2000001786A0 (en) 2000-04-16
CA2306825A1 (en) 1999-04-29
AU9696198A (en) 1999-05-10
BG104432A (bg) 2000-12-29
CN1302206A (zh) 2001-07-04
HUP0101022A1 (hu) 2001-10-28
OA11371A (en) 2004-01-28
NO20003107D0 (no) 2000-06-16
PL344977A1 (en) 2001-11-19
NO20001962D0 (no) 2000-04-14
JP2001520193A (ja) 2001-10-30
EA200000427A1 (ru) 2001-02-26
EP1030665A4 (en) 2002-11-27
EP1030665A1 (en) 2000-08-30
NO20001962L (no) 2000-06-16
BR9814087A (pt) 2000-10-03
KR20010024533A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
NO20003107D0 (no) FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR
NO981360D0 (no) Fremgangsmåte til sammenföyning av metalliske sammenföyningselementer ved hjelp av friksjonsagitasjon
NO955113D0 (no) Anordning og fremgangsmåte ved endostern reaksjon
AU6695098A (en) Apparatus and method for combinatorial chemistry synthesis
DK0811128T3 (da) Fremgangsmåde til at forbinde forede røremner og røremner forbundet ved denne fremgangsmåde
EP0709769A3 (en) Apparatus and method for analysis and resolution of operand dependencies
DK1015662T3 (da) Fremgangsmåde til forebyggelse af korrosion af metaller ved anvendelse af silaner
DK0877752T3 (da) Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler
NO984629L (no) FremgangsmÕte og apparat for topp- og bunnekspansjon av r°r
DK0892035T3 (da) Flerfaseemulsion og fremgangsmåde til fremstilling heraf
BR9708036A (pt) Processo para a análise de um analito e e aparelho analitico
NO983957D0 (no) Fremgangsmåte ved sammenföyning av tofase rustfritt stål
EP1051583A4 (en) METHOD AND DEVICE FOR OPTICAL IMPROVEMENT OF CHEMICAL REACTIONS
AU6215800A (en) Method and apparatus for rapid screening of multiphase reactions
AU2001265351A1 (en) Method and analytical system for rapid screening of combinatorial libraries
DE69806950D1 (de) Neues reaktionsgefäss und verfahren zu dessen verwendung
FR2805044B1 (fr) Procede et dispositif de determination de l'evolution d'une reaction chimique dans un four et de reglage de la reaction
AU7804598A (en) Apparatus and method of providing a personal fertility predictor
AU7062198A (en) Purification of peptides and oligonucleotides by sample displacement chromatography process and apparatus
NO960401L (no) Fremgangsmåte ved fristempelinnretninger og anordning til utförelse av fremgangsmåten
AU6304098A (en) Reaction apparatus for solid phase synthesis and method of using the same
NO20000182D0 (no) Fremgangsmåte for fremstilling av alkoksyfuranonaminderivater, forbindelser frembragt ved fremgangsmåten og anvendelse av disse forbindelser
AU2495499A (en) Supports for solid state chemical reactions and method of use thereof
SI1044364T1 (sl) Postopek in reagenti za kvantifikacijo reakcij v trdni fazi z uporabo NMR s fluorom
DK1044364T3 (da) Fremgangmåde og reagenser til kvantificering af fastfasereaktioner ved anvendelse af fluor-NMR

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application